{
    "organizations": [],
    "uuid": "687b06af6e91f27fb7bd93d3ff74e538246d4fa6",
    "author": "",
    "url": "https://www.reuters.com/article/brief-neurocrine-biosciences-reports-q4/brief-neurocrine-biosciences-reports-q4-earnings-per-share-0-07-idUSASB0C5HN",
    "ord_in_thread": 0,
    "title": "BRIEF-Neurocrine Biosciences Reports Q4 Earnings Per Share $0.07",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "February 13, 2018 / 9:10 PM / in 13 minutes BRIEF-Neurocrine Biosciences Reports Q4 Earnings Per Share $0.07 Reuters Staff 1 Min Read Feb 13 (Reuters) - Neurocrine Biosciences Inc: * NEUROCRINE BIOSCIENCES REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS AND PROVIDES INVESTOR UPDATE FOR 2018 * Q4 EARNINGS PER SHARE $0.07 * Q4 REVENUE $94.5 MILLION * NEUROCRINE BIOSCIENCES- REVENUE MILESTONES UNDER ABBVIE AGREEMENT FOR 2018 EXPECTED TO BE $40 MILLION CONTINGENT ON FDA APPROVAL OF ELAGOLIX FOR ENDOMETRIOSIS * ‍ONGOING OPERATING EXPENSES FOR 2018 SHOULD APPROXIMATE $365 MILLION TO $395 MILLION​ Source text for Eikon: Further company coverage:",
    "published": "2018-02-13T23:09:00.000+02:00",
    "crawled": "2018-02-13T23:29:36.019+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "february",
        "pm",
        "minute",
        "bioscience",
        "report",
        "q4",
        "earnings",
        "per",
        "share",
        "reuters",
        "staff",
        "min",
        "read",
        "feb",
        "reuters",
        "neurocrine",
        "bioscience",
        "inc",
        "neurocrine",
        "bioscience",
        "report",
        "fourth",
        "quarter",
        "financial",
        "result",
        "provides",
        "investor",
        "update",
        "q4",
        "earnings",
        "per",
        "share",
        "q4",
        "revenue",
        "million",
        "neurocrine",
        "revenue",
        "milestone",
        "abbvie",
        "agreement",
        "expected",
        "million",
        "contingent",
        "fda",
        "approval",
        "elagolix",
        "endometriosis",
        "operating",
        "expense",
        "approximate",
        "million",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}